EPO and erythroleukemia: In a haematological model (erythroleukemia), IDH2 mutation caused methylation changes, which were successfully reversed by its inhibitor [18]; similarly, it impaired the EPO-induced differentiation, which was restored upon mutant IDH2 inhibition [28].